Intermittent or daily administration of 1-alpha calcidol for nephrectomised infants on peritoneal dialysis?

Area of Science:

• Pediatric Nephrology
• Endocrinology
• Renal Osteodystrophy

Background:

• Secondary hyperparathyroidism and renal osteodystrophy are significant complications in end-stage renal failure, impacting growth in pediatric dialysis patients.
• The optimal administration schedule (intermittent vs. daily) for vitamin D sterols in these patients remains debated.

Purpose of the Study:

• To compare the efficacy of intermittent versus daily 1-alpha calcidol therapy in managing secondary hyperparathyroidism.
• To evaluate the impact of different administration schedules on growth in infants with congenital nephrosis undergoing peritoneal dialysis.

Main Methods:

• A study involving 16 infants with congenital nephrosis on peritoneal dialysis, divided into groups receiving intermittent or daily 1-alpha calcidol.
• Monitoring of serum parathyroid hormone (PTH) levels and assessment of growth (standard deviation scores) over 6 months.
• Analysis of weekly 1-alpha calcidol dosage requirements.

Main Results:

• Both intermittent and daily 1-alpha calcidol effectively controlled PTH levels, with no statistically significant differences between groups.
• Low weekly doses of 1-alpha calcidol were sufficient in both treatment arms.
• Infants receiving intermittent 1-alpha calcidol demonstrated significantly better catch-up growth compared to those on daily therapy.

Conclusions:

• Early initiation of either intermittent or daily vitamin D analogue therapy is equally effective in preventing secondary hyperparathyroidism in children on peritoneal dialysis.
• Intermittent vitamin D analogue therapy may offer a growth advantage in pediatric patients with end-stage renal failure compared to daily administration.